This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Fourth Look at Efruxifermin as a therapy for nonalcoholic steatohepatitis
Ticker(s): AKROWho's the expert?
Institution: Predictive Health
- Dr. Brill is Board Certified in Internal Medicine and Gastroenterology. Dr. Brill has run risk-bearing Independent Practice Associations and Physician-Hospital Organizations in California and Arizona, held management positions with and participates on committees for several managed care companies. He was the Medical Director for the BFCC.NCC-Q1O oversight project during the 12th SOW, serves on the Editorial Advisory Board for several journals, and was the co-founder of the AGA Center for Gl Innovation and Technology.
- Currently manages ~10 NASH patients and can speak to efruxifermin and its HARMONY Phase IIb trial data
- Dr. Brill is an Assistant Clinical Professor of Medicine at the University of Arizona College of Medicine, and an Adjunct Assistant Professor of Medicine at Midwestern University. He has lectured at the School of Health Management & Policy at the WP Carey School of Business at Arizona State University.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
